logo

For the Inventor, By the Inventor

Wayne, PA, United States of America

Michael J Kelly, Iii

This inventor holds 15 USPTO granted patents and 11 published patent applications. Top assignees: Merck Sharp + Dohme Corp., Msd R&d (China) Co., Ltd., Walter and Eliza Hall Institute of Medical Research. Active years: 2009-2025.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Michael J Kelly, Iii. Retrieved from https://idiyas.com/inventor/michael-j-kelly-iii

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 15 

% Patents Active = 100.0

Average Co-Inventor Count = 5.7

ph-index = 2

Forward Citations = 26(Granted Patents)


Location History:

  • Wayne, PA (US) (2009 - 2016)
  • Paoli, PA (US) (2016 - 2023)

Company Filing History:

goldMedal13 out of 2,405 
 
Merck Sharp + Dohme Corp.
 patents
silverMedal2 out of 10 
 
Msd R&d (China) Co., Ltd.
 patents
bronzeMedal2 out of 84 
 
Walter and Eliza Hall Institute of Medical Research
 patents
4. 1 out of 1 
 
Merch Sharpe & Dohme LLC
 patent
5. 1 out of 4,770 
 
Merck + Co., Inc.
 patents
where one patent can have more than one assignee

Years Active: 2009-2025

Loading Chart...
15 patents (USPTO):Explore Patents
1. 12350270 - Antimalarial agents (2025-07-08),
2. 12338219 - Antimalarial agents (2025-06-24),
3. 12246008 - 4-amino or 4-alkoxy-substituted aryl sulfonamide compounds with selective activity in voltage-gated sodium channels (2025-03-11),
4. 11802122 - 2-oxoimidazolidine-4-carboxamides as NA1.8 inhibitors (2023-10-31),
5. 10519147 - Diamino-alkylamino-linked arylsulfonamide compounds with selective activity in voltage-gated sodium channels (2019-12-31),
6. 10442778 - N1-phenylpropane-1,2-diamine compounds with selective activity in voltage-gated sodium channels (2019-10-15),
7. 9624208 - Benzoxazolinone compounds with selective activity in voltage-gated sodium channels (2017-04-18),
8. 9388179 - N-substituted indazole sulfonamide compounds with selective activity in voltage-gated sodium channels (2016-07-12),
9. 9315518 - Imidazopyridin-2-one derivatives (2016-04-19),
10. 9273040 - Benzoxazolinone compounds with selective activity in voltage-gated sodium channels (2016-03-01),
11. 9108937 - Positive allosteric modulators of mGluR2 (2015-08-18),
12. 8952005 - Substituted 1,3-benzothiazol-2(3H)-ones and [1,3]thiazolo[5,4-B]pyridin-2(1H)-ones as positive allosteric modulators of mGluR2 (2015-02-10),
13. 8288407 - Substituted naphthyridine compounds as inhibitors of Akt activity (2012-10-16),
14. 8008317 - Inhibitors of akt activtiy (2011-08-30),
15. 7576209 - Inhibitors of Akt activity (2009-08-18),

Title: Michael J Kelly, III: A Pioneer in Pain Management Innovations

Introduction

Michael J Kelly, III is a notable inventor based in Wayne, Pennsylvania, recognized for his significant contributions to the field of pharmaceuticals. With a portfolio of 13 patents, Kelly has made substantial advancements in the development of compounds aimed at treating various pain disorders, cough, and itch disorders.

Latest Patents

Among his latest innovations, Kelly has developed compounds known as 4-amino or 4-alkoxy-substituted aryl sulfonamide compounds, which exhibit selective activity in voltage-gated sodium channels. This set of compounds, detailed in his patents, inhibits Nav 1.7 ion channels prevalent in peripheral and sympathetic neurons. The patents describe not only the formula of these compounds but also their potential applications in pharmaceutical formulations for treating pain disorders, coughs, and itch.

Additionally, he has introduced 2-oxoimidazolidine-4-carboxamides as inhibitors of Na1.8 channel activity. These novel compounds can play a critical role in managing diseases related to Na1.8 channel activity, presenting promising therapeutic options for pain and itch disorders.

Career Highlights

Michael has had a distinguished career with influential companies such as Merck Sharp & Dohme Corporation and Merck & Company, Inc. His work has greatly impacted the pharmaceutical industry, particularly in the development of innovative treatments that address complex health issues.

Collaborations

Throughout his career, Kelly has collaborated with talented individuals including Mark E Layton and Joseph E Pero. These collaborations have fostered an environment of creativity and innovation, leading to numerous breakthroughs in pharmaceutical research and development.

Conclusion

Michael J Kelly, III exemplifies the spirit of innovation in pharmaceuticals through his significant patents and collaborations. His work continues to inspire future advancements in the treatment of pain and related disorders, securing his place as a prominent figure in the field of inventors.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…